Our 6-month interim analysis of the FURGGHORN study, has been published in the latest issue of the Asia-Pacific Journal of Ophthalmology. https://lnkd.in/gRxscBx8.

The FURGGHORN study is an investigator initiated trial, evaluating the effect of switching to faricimab therapy patients with neovascular age-related macular degeneration currently treated with anti-VEGF therapy.

We extend our sincere appreciation to all collaborators and contributors whose dedication made this achievement possible.